The US Food and Drug Administration (FDA) approved human papillomavirus vaccination for men and women from 27 to 45 years old – before it was recommended only for people over 26 years old. This is stated in the message on the FDA website, in addition, the vaccine tells the New York Times.
Human papillomavirus is a group of viruses that has about 27 species and more than 600 strains (types), some of which have oncogenic properties: HPV, for example, is considered the main cause of cervical cancer. Viruses of this group have a long incubation period and are transmitted mainly through sexual contact. For the prevention of infection with oncogenic HPV strains (and, in particular, for protection against cervical cancer), in 2006, the American company Merck & Co developed the Gardasil vaccine , then it appeared similar, Cervarix from the British company GlaxoSmithKline.
Now the vaccine “Gardasil 9”, which protects against the nine most dangerous strains from the point of view of cancer development, has been approved for use in people from 27 to 45 years old – previously, only up to 26 years were vaccinated. Vaccination is still recommended to be done at adolescence until the start of sexual activity, since the vaccine does not protect against HPV strains with which a person is already infected. However, their diversity and the fact that “Gardasil 9” protects from several strains at once, makes the vaccination justified for adults, according to FDA experts.
According to the newspaper, the vaccine was approved, guided by data from clinical trials on women and men aged 27-45, which confirmed its safety and high efficacy in preventing cancer of the genital organs and cervix. Adults will need three injections over several months. The most common side effects of vaccination are redness and swelling at the injection site and headaches.
Dr. Lois Ramondetta from the Houston Cancer Research Center, interviewed by the New York Times, noted that the new FDA recommendations would better protect against cancer a generation of people who were unavailable during adolescence.
Two years ago, Japanese scientists published an article in Scientific Reports demonstrating that a vaccine against human papillomavirus could cause brain damage. True, the experiments conducted by the authors of the article on mice did not correspond to the purpose of the study and contained methodological errors, as indicated by independent experts. As a result of the controversy that broke out, the editors decided to withdraw the controversial article, despite the protests of the authors.